Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Gan & Lee Pharmaceuticals.: Strengths and Weaknesses

Highlights: Gan & Lee Pharmaceuticals.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Gan & Lee Pharmaceuticals.
  • The company does not generate enough profits, which is an alarming weak point.
  • With a 2025 P/E ratio at 35.83 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Rating Financials

Gan & Lee Pharmaceuticals. SectorChina
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth-
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth-
Long term revenue growth-
Long term EPS growth
More ratings

Rating Valuation

Gan & Lee Pharmaceuticals. SectorChina
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF-
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Gan & Lee Pharmaceuticals. SectorChina
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Gan & Lee Pharmaceuticals. SectorChina
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Gan & Lee Pharmaceuticals. SectorChina
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
5.59B -
76.06B
A
58.92B
AA
53.01B
BBB
52.48B
AA
25.54B
AA
18.76B
AAA
18.73B
AA
15.67B
CCC
14.48B -
BB
- -
Average 33.92B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. 603087 Stock
  4. Ratings Gan & Lee Pharmaceuticals.